Key result
Major cardiovascular events complicates ~6% of elective chemotherapy hospitalizations and is linked to increased in-hospital mortality.
Why the study?
Contemporary data describing acute cardiovascular events during elective chemotherapy hospitalizations were limited, and the incidence, predictors, and short-term clinical impact of MACE during planned admissions remained poorly characterized.
Cohort (n=7,874,281)
Yes
MACE occurs in approximately 5.8% of elective chemotherapy admissions and is associated with significantly increased in-hospital mortality, length of stay, and healthcare costs.
Answers are grounded in this paper and cite their sources.
MACE risk during elective chemotherapy may heighten surveillance; leaves open causal mechanisms and prevention trials.
e24020 Background: Cardiovascular complications represent a major source of morbidity among patients receiving systemic chemotherapy, yet contemporary data describing acute cardiovascular events during elective chemotherapy hospitalizations are limited. While prior studies have focused on long-term cardiotoxicity, the incidence, predictors, and short-term clinical impact of major adverse cardiovascular events (MACE) occurring during planned inpatient chemotherapy admissions remain poorly characterized. Methods: We conducted a retrospective cohort study using the National Inpatient Sample (NIS). Adult elective hospitalizations involving chemotherapy administration were identified using ICD-10-PCS codes. MACE was defined as a composite of acute MI, ischemic stroke, acute heart failure, or malignant arrhythmias. Multivariable survey-weighted logistic regression models were used to identify predictors of MACE and to evaluate associations with in-hospital mortality and resource utilization, adjusting for demographics, comorbidities, metastatic disease, and hospital characteristics. Results: Among 7,874,281 elective chemotherapy hospitalizations, 5.8% experienced at least one MACE. Patients with MACE were older (65.4 vs 38.8 years, p < 0.001) and more frequently male (55.1% vs 44.8%, p < 0.001). Independent predictors of MACE included older age (aOR 1.03), African American race versus White (aOR 1.21), obesity (aOR 1.30), obstructive sleep apnea (aOR 1.42), coronary artery disease (aOR 3.48), hyperlipidemia (aOR 1.47), peripheral vascular disease (aOR 1.35), sepsis (aOR 3.26), and anemia (aOR 1.31) (all p < 0.001). Female sex was independently protective (aOR 0.92). Solid tumors were associated with lower odds of MACE compared with hematologic malignancies (aOR 0.17). Metastatic disease and tumor lysis syndrome were not independently associated with MACE. MACE was strongly associated with increased in-hospital mortality (aOR 4.83), higher total hospitalization costs (+$78,844), and longer length of stay (+2.85 days) (all p < 0.001). Conclusions: MACE occurs in nearly 1 in 17 elective chemotherapy hospitalizations and is associated with substantial increases in mortality, length of stay, and healthcare costs. Patients with hematologic malignancies and pre-existing cardiovascular comorbidities are at particularly high risk. These findings highlight the need for improved cardiovascular risk stratification and inpatient monitoring strategies during elective chemotherapy admissions.
No takes yet. Share an insight, caveat, or question.
Assaf et al. (2026) conducted a cohort in Elective hospitalizations involving chemotherapy administration (n=7,874,281). Elective chemotherapy was evaluated on Major adverse cardiovascular events (MACE) (composite of acute MI, ischemic stroke, acute heart failure, or malignant arrhythmias). Major adverse cardiovascular events occurred in 5.8% of elective chemotherapy hospitalizations and were strongly associated with increased in-hospital mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: